Skip to main
CAI

CAI (CAI) Stock Forecast & Price Target

CAI (CAI) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Caris Life Sciences is a promising investment opportunity as the company's projected revenue for 2026 has been raised due to strong performance in the first quarter, and they expect a 20% increase in clinical growth. With a new cancer detection test, a strong investor base, and an experienced management team, the company plans to aggressively advertise its ability to detect cancer at earlier stages and expand their sales team. Additionally, their partnerships with over 100 biopharma companies and development of a comprehensive genomic profiling test provide further potential for growth. However, there may be legal risks in the competitive marketplace that could impact the company's success.

Bears say

Caris Life Sciences is facing valuation risks and competition in precision oncology diagnostics from other established laboratory companies, as well as potential legal risks in a highly competitive marketplace. The company's recent launch into the cancer screening market may provide upside potential, but there are development, reimbursement, and commercialization risks to consider. Additionally, Caris may need to raise additional capital to pursue their expansion plans, which could pose a risk to the balance sheet. Overall, there are potential obstacles and uncertainties in the company's future growth and profitability, leading to a negative outlook.

CAI (CAI) has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CAI and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CAI (CAI) Forecast

Analysts have given CAI (CAI) a Buy based on their latest research and market trends.

According to 9 analysts, CAI (CAI) has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.11, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.11, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CAI (CAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.